Rising Chronic Kidney Disease Prevalence Sparks Global Dialysis Market Growth
Dialysis demand is likely to grow at a compound rate of 7.7 % percent a year until FY30, The rise...
Disease
Patients with chronic liver disease face emotional conflicts during carcinoma surveillance
The left panel illustrates the living cycle, including regular health care visits. The right panel depicts the process of adjusting...
Using hyperhomocysteinemia and body composition to predict the risk of non-alcoholic fatty liver disease in healthcare workers
1. IntroductionThe prevalence of NAFLD is approximately 25%, and continues to rise along with global obesity rates (1, 2). NALFD,...
Factors associated with chronic kidney disease in patients with diabetes in French Guiana
1 IntroductionDiabetes is a major public health problem. The prevalence of diabetes continues to increase worldwide, mainly in developing countries....
Is End-Stage Renal Disease Treatment Choices Model Moving the Needle?
A recent JAMA Health Forum study found that the Centers for Medicare & Medicaid Services’ End-Stage Renal Disease Treatment Choices...
FDA Approves Gilead’s Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal – Gilead Sciences (NASDAQ:GILD)
On Wednesday, the FDA granted accelerated approval for Gilead Sciences, Inc.’s GILD Livdelzi (seladelpar) for primary biliary cholangitis (PBC) in combination with...
